How to Help Your Patients Find Zarxio in Stock: A Provider's Guide

Your Patients Need Zarxio — Here's How to Help Them Get It

As a provider managing patients on myelosuppressive chemotherapy, you know that timely G-CSF administration is critical. When your patient calls to say they can't find Zarxio (filgrastim-sndz) at their pharmacy, it's not just an inconvenience — it's a potential clinical problem. Delayed G-CSF increases the risk of febrile neutropenia, treatment delays, and hospitalizations.

The Zarxio shortage has been affecting patients and practices for several years now, and while supply is gradually improving, gaps persist. This guide provides a practical, step-by-step approach your team can use to help patients access their G-CSF medication — whether that's Zarxio or an appropriate alternative.

Current Availability: Where Things Stand

As of early 2026, Zarxio availability varies significantly by channel and geography:

• Specialty pharmacies serving oncology patients generally report the most reliable stock levels
• Hospital and health system pharmacies have mixed availability depending on their group purchasing organization (GPO) contracts
• Retail chains (CVS, Walgreens, etc.) tend to run out fastest due to high patient volume
• Regional variation is significant — some areas have near-normal supply while others face ongoing gaps

The FDA continues to monitor filgrastim supply, and additional biosimilar entrants are helping stabilize the market. But supply has not fully normalized, and proactive management remains essential.

Why Patients Can't Find Zarxio

Understanding the bottlenecks helps you guide patients more effectively:

• Manufacturing complexity: As a biologic, Zarxio requires specialized production from living cells. Quality issues can shut down entire production runs
• Few manufacturers: The filgrastim market has a small number of producers. A disruption at one facility has outsized impact
• Cold chain requirements: Zarxio must be refrigerated throughout storage and shipping, adding logistical complexity
• Distribution imbalances: Wholesalers may allocate inventory unevenly, leaving some pharmacies with stock while others are empty
• Patients default to retail chains: Most patients go to their usual pharmacy first. Large retail chains deplete their allocation quickly

For a detailed background, see our shortage briefing: Zarxio shortage: What providers need to know in 2026.

5 Steps to Help Your Patients Find Zarxio

Step 1: Direct Patients to Medfinder

The single most impactful step you can take is to point patients to Medfinder. This free, real-time tool lets patients (and your staff) search for pharmacies with Zarxio in stock by zip code.

Consider adding Medfinder to your practice's patient-facing materials:

• Include it on after-visit summaries for patients starting chemotherapy
• Add it to your practice website or patient portal
• Train your nursing and pharmacy staff to recommend it during shortage periods

Patients can visit medfinder.com on any device — no account needed.

Step 2: Establish Specialty Pharmacy Relationships

If your practice doesn't already partner with an oncology-focused specialty pharmacy, this is the time to establish that relationship. Specialty pharmacies:

• Maintain dedicated oncology medication inventory
• Have priority access to shortage-affected products through their wholesaler relationships
• Can coordinate directly with your prescribing and nursing teams
• Often handle prior authorization on the patient's behalf

Having a go-to specialty pharmacy means your staff has a single point of contact when a patient can't find Zarxio elsewhere.

Step 3: Prescribe With Flexibility

When writing G-CSF prescriptions, consider building in flexibility from the start:

• Add "or therapeutic equivalent" to the prescription when clinically appropriate, giving the pharmacist latitude to fill with an available filgrastim product
• Maintain active prescriptions for both short-acting and long-acting G-CSF options so patients can switch quickly if one is unavailable
• Pre-authorize alternatives with the patient's insurer before the shortage creates an urgent situation

This proactive approach saves time when a specific product is unavailable and prevents treatment delays.

Step 4: Leverage Your Health System's Supply

If your practice is affiliated with a hospital or health system, explore in-house options:

• Outpatient pharmacy dispensing: Many hospitals can dispense Zarxio directly from their pharmacy to ambulatory patients
• Clinic-administered doses: If appropriate, patients can receive their injections on-site rather than self-administering at home
• Bulk purchasing advantages: Health systems with GPO contracts may have more reliable access to shortage-affected products

Step 5: Communicate Proactively

Don't wait for patients to call you in a panic. Proactive communication helps patients plan ahead:

• Discuss potential availability challenges at the time of prescribing
• Provide patients with a written plan: "Try pharmacy A first. If unavailable, try pharmacy B. If still unavailable, call our office."
• Alert your nursing team to follow up with patients 2 to 3 days before their G-CSF start date to confirm they have their medication

Alternatives to Zarxio

When Zarxio is unavailable, the following G-CSF products are clinically appropriate substitutes for most patients:

• Neupogen (filgrastim): The reference product. Identical mechanism. Higher cost ($500–$900/syringe)
• Granix (tbo-filgrastim): Another short-acting G-CSF. Similar efficacy and safety profile
• Neulasta (pegfilgrastim): Long-acting option. One injection per chemo cycle. Significantly more expensive ($5,000–$8,000/dose)
• Udenyca (pegfilgrastim-cbqv): Biosimilar to Neulasta. One injection per cycle at lower cost than brand Neulasta

See our patient-facing guide on alternatives to Zarxio for detailed comparisons you can share with patients.

Workflow Tips for Your Practice

Here are some practical workflow changes that can help your team manage the shortage more efficiently:

Create a Shortage Protocol

Develop a written protocol that your nursing, pharmacy, and front-desk staff can follow when patients report they can't find Zarxio. Include:

• A checklist of pharmacies to try (starting with your preferred specialty pharmacy)
• Clear escalation steps: nurse → pharmacist → prescriber
• Template language for formulary exception requests
• A list of approved alternative medications

Batch Prior Authorization Requests

If you're seeing a pattern of patients unable to fill Zarxio prescriptions, consider proactively submitting PA requests for alternatives for upcoming patients. This way, when a patient can't find Zarxio, they can immediately switch to an already-authorized alternative.

Track Availability Trends

Designate someone on your team — a pharmacy tech, nurse, or practice manager — to check Zarxio availability weekly using Medfinder and the FDA drug shortage database. Understanding trends helps you anticipate problems before they affect patient care.

Educate Your Patients

Create a one-page handout for patients starting G-CSF therapy that includes:

• What to do if their pharmacy doesn't have Zarxio
• A link to Medfinder
• Your office phone number for medication access questions
• Names of alternative G-CSF medications they may receive

Final Thoughts

The Zarxio shortage demands a proactive, multi-channel approach from providers. By integrating real-time tools like Medfinder into your workflow, maintaining specialty pharmacy relationships, prescribing with flexibility, and communicating proactively with patients, you can significantly reduce the risk of treatment delays.

Your patients are already dealing with the stress of cancer treatment. Helping them navigate medication access shouldn't add to that burden. A few small workflow changes can make a big difference.

For the clinical and market context behind these recommendations, see our companion briefing: Zarxio shortage: What providers and prescribers need to know in 2026.